Verve Therapeutics, Inc. (VERV): Price and Financial Metrics

Verve Therapeutics, Inc. (VERV): $6.66

0.08 (-1.19%)

POWR Rating

Component Grades

Momentum

C

Stability

F

Sentiment

Quality

C

Add VERV to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#263 of 363

in industry

VERV Price/Volume Stats

Current price $6.66 52-week high $21.42
Prev. close $6.74 52-week low $6.53
Day low $6.53 Volume 1,246,419
Day high $6.86 Avg. volume 1,242,455
50-day MA $12.32 Dividend yield N/A
200-day MA $13.50 Market Cap 556.90M

VERV Stock Price Chart Interactive Chart >


Verve Therapeutics, Inc. (VERV) Company Bio


Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease.


VERV Latest News Stream


Event/Time News Detail
Loading, please wait...

VERV Latest Social Stream


Loading social stream, please wait...

View Full VERV Social Stream

Latest VERV News From Around the Web

Below are the latest news stories about VERVE THERAPEUTICS INC that investors may wish to consider to help them evaluate VERV as an investment opportunity.

Wall Street Analysts Believe Verve Therapeutics (VERV) Could Rally 260.31%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 260.3% in Verve Therapeutics (VERV). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Yahoo | December 13, 2023

Verve Therapeutics Announces Closing of Public Offering of Common Stock, Full Exercise by Underwriters of Option to Purchase Additional Shares and Closing of Concurrent Private Placement

BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the closing of its previously announced underwritten public offering of 14,375,000 shares of its common stock at a public offering price of $10.00 per share, which includes 1,875,000 shares issued upon the exercise in full by the underwriters of their opt

Yahoo | December 1, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Pre-market stock movers are a good way to start the day as we dive into the biggest news worth checking out on Wednesday morning!

William White on InvestorPlace | November 29, 2023

Verve Therapeutics Announces Pricing of Public Offering of Common Stock and Concurrent Private Placement

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $10.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and other offering

Yahoo | November 29, 2023

Verve Therapeutics Announces Proposed Public Offering of Common Stock and Concurrent Private Placement

BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc. (Nasdaq: VERV), a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Verve. In addition, Verve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of it

Yahoo | November 28, 2023

Read More 'VERV' Stories Here

VERV Price Returns

1-mo -48.81%
3-mo -44.22%
6-mo -28.23%
1-year -58.68%
3-year N/A
5-year N/A
YTD -52.22%
2023 -27.96%
2022 -47.52%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!